Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis

A retrospective analysis of data from 209 patients with myelofibrosis who were treated with ruxolitinib between 2006 and 2015 suggests that patients may have increased morbidity burden after discontinuing ruxolitinib therapy. In the study, half of the patients developed cytopenias after ruxolitinib discontinuation. In addition, most patients were diagnosed with anemia and more than 30% underwent red blood cell transfusions 30 days prior to and post-ruxolitinib discontinuation.